

MANAGEMENT SYSTEM CERTIFICATE

Certificate no.: C705686

Initial certification date: 15 December 2006

Valid:

15 December 2024 - 14 December 2027

This is to certify that the management system of

Suven Pharmaceuticals Limited

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081, Telangana, India

and the sites as mentioned in the appendix accompanying this certificate

has been found to conform to the Environmental Management System standard:

ISO 14001:2015

This certificate is valid for the following scope:

Research and manufacture of formulations, bulk actives, drug intermediates and fine chemicals

Place and date: Barendrecht, 27 August 2024 For the issuing office: DNV - Business Assurance Zwolseweg 1, 2994 LB Barendrecht, Netherlands







Erie Koek
Management Representative





Certificate no.: C705686 Place and date: Barendrecht, 27 August 2024

Appendix to Certificate

Suven Pharmaceuticals Limited

Locations included in the certification are as follows:

Site Name	Site Address	Site Scope
Suven Pharmaceuticals Limited	Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081, Telangana, India	Top management, marketing, purchase and HR Activities
Suven Pharmaceuticals Limited	Suryapet Unit: Dasaigudem, Suryapet (M), Suryapet (Dist.) - 508213, Telangana, India	In process development, manufacturing of drug intermediates and fine chemicals
Suven Pharmaceuticals Limited	Plot Nos. 65 to 67, JN Pharma city, Thanam (V), Parawada (M), Visakhapatnam - 531019, Andhra Pradesh, India	In process development, manufacturing of drug intermediates and fine chemicals
Suven Pharmaceuticals Limited	Jeedimetla Unit: Plot No-18, Phase - III,IDA,Jeedimetla,Hyderabad - 500 055, Telangana, India	Research and manufacturing of drug intermediates and fine chemicals
Suven Pharmaceuticals Limited	Pashamylaram Unit :, Plot.No.262 to 271, IDA, Pashamylaram, Pashamylaram - 502 307, Telangana, India	In process development, manufacturing of bulk actives, drug intermediates and formulation